Compare Adaptive Biotechnologies Corp (ADPT) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wahed FTSE USA Shariah ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Wahed FTSE USA Shariah ETF trades at $70.6. Which is the better fit depends on your goals.
| ADPT | HLAL | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $73.60 |
52-Week Low | $10.24 | $53.83 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HLAL trades at $71.16, up 1.22% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $71-$73, with support at $70 and $69. Recent dividend activity includes a $0.02 distribution scheduled for June 2026, though key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity.
The outlook remains cautious due to weak technical momentum and lack of recent financial data. Risks include market volatility and potential earnings uncertainty, while opportunities hinge on future corporate updates. Investors should await fresh earnings reports for a clearer valuation picture amid current bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
